STAT1 and breast cancer: Next, we asked if the inhibitor’s effects on TILs and anti-tumor immunity in AT3-OVA mammary tumors might nonetheless occur as a consequence of enhanced intratumoral T cell activation and resultant inflammatory STAT-1 signaling in tumors.